



C/C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 7,045,617) Serial No. 09/811,870
Inventor(s): Philip A. COLE *et al*) Filed: March 21, 2001
Issue Date: May 16, 2006) Attorney Docket No. 001107.00108

For: BISUBSTRATE INHIBITIONS OF KINASES

REQUEST FOR CERTIFICATE OF CORRECTION

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop: Certificate of Correction Branch
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, this is a request for the issuance of a Certificate of Correction in the above-identified patent. Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves one page.


The mistakes identified in the appended Form occurred through no fault of the Applicants, as clearly disclosed by the records of the application, which matured into this patent. Enclosed for your convenience are the relevant portions of the Declaration filed September 24, 2001 and Amendment after Final filed November 3, 2005.

Issuance of the Certificate of Correction containing the corrections is respectfully requested. Since these changes are necessitated through no fault of the Applicants, no fee is believed to be associated with this request. Nonetheless, should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By:


Sarah A. Kagan
Registration No. 32,141

Certificate
SEP 25 2006
of Correction

Dated: September 21, 2006

1001 G Street, N.W. (11th Fl.)
Washington, D.C. 20001
(202) 824-3000

'SEP 26 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,045,617

DATED: May 16, 2006

INVENTOR(S): Philip A. COLE *et al*


It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Cover Page, Title section (54):


Please replace "BISUBSTRATE" with --BISUBSTRATE--

In Columns 17-18, Claim 1:

Please replace the formula as it appears below:



with the formula shown below (with three oxygen molecules having a negative charge):



Mailing Address of Sender:

Banner & Witcoff, Ltd.
11th Floor
1001 G Street, N.W.
Washington, DC 20001-4597

U.S. PAT. NO 7,045,617

No. of add'l copies
@ \$0.50 per page

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,045,617

DATED: May 16, 2006

INVENTOR(S): Philip A. COLE *et al*


It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Cover Page, Title section (54):


Please replace "BISBUBSTRATE" with --BISUBSTRATE--

In Columns 17-18, Claim 1:

Please replace the formula as it appears below:



with the formula shown below (with three oxygen molecules having a negative charge):



Mailing Address of Sender:

Banner & Witcoff, Ltd.
11th Floor
1001 G Street, N.W.
Washington, DC 20001-4597

U.S. PAT. NO 7,045,617

No. of add'l copies
@ \$0.50 per page

JOINT DECLARATION FOR PATENT APPLICATION

As the below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our names;

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled BISUBSTRATE INHIBITORS OF KINASES, the specification of which is attached hereto. was filed on March 21, 2001 as Application Serial Number 09/811,870 and was amended on _____ (if applicable). was filed under the Patent Cooperation Treaty (PCT) and accorded International Application No. _____, filed _____, and amended on _____ (if any).

SEP 21 2001
U.S. PATENT & TRADEMARK OFFICE

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We hereby acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

Prior Foreign Application(s)

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application No.	Date of Filing (day month year)	Date of Issue (day month year)	Priority Claimed Under 35 U.S.C. §119

Prior United States Provisional Application(s)

We hereby claim priority benefits under Title 35, United States Code, §119(e)(1) of any U.S. provisional application listed below:

U.S. Provisional Application No.	Date of Filing (day month year)	Priority Claimed Under 35 U.S.C. §119(e)(1)
60/190,799	21 March 2000	Yes

Prior United States Application(s)

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Date of Filing (Day, Month, Year)	Status — Patented, Pending, Abandoned

RECEIVED
CENTRAL FAX CENTER

NOV 03 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Confirmation No. 8634
Philip A. COLE *et al.*)
Serial No. 09/811,870) Group Art Unit: 1652
Filed: March 21, 2001) Examiner: D. Steadman
For: Bisubstrate Inhibitors of Kinases) Atty. Dkt. No. 001107.00108

AMENDMENT AFTER FINAL REJECTION

Commissioner of Patents
c/o Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In response to the final Office Action mailed May 18, 2005, and the Advisory Action mailed October 24, 2005, applicants request reconsideration of the patentability of the pending claims and entry of this amendment. A petition for two-month's extension of time accompanies this amendment in order to make it timely. If it is determined that other fee is required to enter this amendment, please charge our Deposit Account No. 19-0733.


Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

IN THE CLAIMS

1.-14. (Cancelled)

15. (Currently amended) A bisubstrate inhibitor of insulin receptor kinase, wherein the bisubstrate inhibitor of insulin receptor kinase is Compound 2;

 $R_1 = \text{AcNH-Lys-Lys-Lys-Leu-Pro-Ala-Thr-Gly-Asp}$ (SEQ ID NO:3) $R_2 = \text{Met-Asn-Met-Ser-Pro-Val-Gly-Asp-CO}_2\text{H}$ (SEQ ID NO:4)

16-88. (Cancelled)